GURU.Markets stock price, segment price, and overall market index valuation
The company's share price KALA BIO Inc.
Shares of KALA BIO, a biopharmaceutical company focused on treating eye diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company that, following a restructuring, has shifted its focus to developing therapeutics for rare vision-related diseases. We classify it within the "Pharmaceuticals (Eye Diseases)" segment, where it is seeking its niche. The chart below illustrates the dynamics of this specialized and complex sector.
Broad Market Index - GURU.Markets
KALA BIO is a biopharmaceutical company developing drugs based on its mucosal drug delivery platform, specifically for the treatment of ocular diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market.
Change in the price of a company, segment, and market as a whole per day
KALA - Daily change in the company's share price KALA BIO Inc.
The daily fluctuations of KALA BIO, Inc. shares are a measure of the extreme volatility inherent in biotech companies. This indicator reflects sensitivity to clinical trial data and FDA decisions, serving as a critical component of risk assessment on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma eyes
KALA BIO, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KALA, which focuses on eye disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
KALA BIO is a biotech company specializing in the treatment of eye diseases. Its share price depends on clinical trial success and regulatory approval. These biotech-specific events create unique price movements that contribute to overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization KALA BIO Inc.
For KALA BIO, Inc., the year-over-year performance is a story of its strategic pivot. Its 12-month market cap change reflects its decision to focus on developing therapies for rare diseases associated with protease deficiency following the sale of its commercial ophthalmology business. Its valuation reflects a bet on a new scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma eyes
KALA BIO, Inc. is a biotech company developing drugs for the treatment of eye diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
KALA BIO is a biotech company whose stock performance is driven by sales success of its eye care products and research progress. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization KALA BIO Inc.
KALA BIO is a biopharmaceutical company focused on eye diseases. Its monthly price performance reflects its clinical and commercial success. News of new FDA drug approvals and quarterly sales reports for existing drugs are the main drivers of its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. Their technology is aimed at improving drug delivery to ocular tissue. The graph below shows the overall dynamics in the ophthalmic pharmaceutical sector, where innovative delivery methods may be key to success.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially after restructurings, can move on their own news. The chart below shows the overall sentiment. Is KALA BIO living its own life, with investors focusing on the potential of a new research direction?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization KALA BIO Inc.
Shares of KALA BIO, a biopharmaceutical company focused on eye diseases, reflect progress in ophthalmology on a weekly basis. Price movements reflect clinical trial data and the commercial potential of their drugs for treating rare and common eye diseases.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
KALA BIO is a pharmaceutical company specializing in the treatment of eye diseases. Success in this niche depends on regulatory approval of new drugs and their commercial launch. This chart allows us to separate the company's news from the overall market: is KALA's share price performance a story of its own or a trend in ophthalmology as a whole?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
KALA BIO is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does KALA BIO live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
KALA - Market capitalization of the company KALA BIO Inc.
KALA BIO's market capitalization tells the story of a biotech company that, after failing in one area (eye diseases), pivoted to another. Its chart reflects this risky shift in strategy. Its dynamics reflect investors' assessment of the potential of its new platform for delivering drugs to previously inaccessible tissues and organs.
KALA - Share of the company's market capitalization KALA BIO Inc. within the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company focused on developing treatments for rare eye diseases. Its market capitalization reflects the potential of its scientific platform to develop new drugs. The chart below shows how investors view its prospects in this highly specialized area of ophthalmology.
Market capitalization of the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company focused on eye diseases. The chart below shows the overall market capitalization of this sector. Its dynamics reflect the ongoing need for new treatments, where KALA BIO is trying to find its niche with its unique drug delivery technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
KALA BIO is a biopharmaceutical company focused on eye diseases. Its market cap reflects the potential of its technologies to offer new solutions for treating and improving vision. Its performance on the overall chart reflects the progress and setbacks in ophthalmological science.
Book value capitalization of the company, segment and market as a whole
KALA - Book value capitalization of the company KALA BIO Inc.
KALA BIO's book value is its capital, which is dedicated to developing a new generation of therapies for rare eye diseases using mesenchymal stem cells. This is a real, scientific foundation for breakthrough ophthalmology. How has this biotech asset changed? The chart below shows its dynamics.
KALA - Share of the company's book capitalization KALA BIO Inc. within the market segment - Pharma eyes
KALA BIO develops therapies for rare eye diseases, requiring specialized laboratories and manufacturing facilities. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its ophthalmic innovations.
Market segment balance sheet capitalization - Pharma eyes
KALA BIO is a biotech company focused on eye diseases. Its main assets are patents, not factories. The book value chart shows how "light" its material base is, while most of its value is created in laboratories.
Book value of all companies included in the broad market index - GURU.Markets
KALA BIO, Inc. focuses on treating eye diseases. Its book value is represented by its laboratories, clinical trial capital, and manufacturing contracts. The chart shows the material foundation upon which its vision preservation and improvement research is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - KALA BIO Inc.
KALA BIO's balance sheet is its capital. Its market price reflects the hope for its new technology for delivering drugs to the eyes. The chart shows the "faith coefficient" in this platform. It can soar on good news from the clinic or plummet to zero on bad news.
Market to book capitalization ratio in a market segment - Pharma eyes
KALA BIO is a biopharmaceutical company focused on treating eye diseases. Its value depends on the success of its drugs in clinical trials and their subsequent commercialization. The chart shows investor expectations for its scientific platform.
Market to book capitalization ratio for the market as a whole
KALA BIO is a biotech company that, after a series of setbacks, has shifted its focus to developing therapies for rare eye diseases. It's attempting a relaunch with a new focus. This chart shows the overall market valuation, but how do investors evaluate a company struggling to find its niche after its initial strategy failed to live up to expectations?
Debts of the company, segment and market as a whole
KALA - Company debts KALA BIO Inc.
KALA BIO, a biotech company focused on eye diseases, addresses highly specialized medical needs. This chart shows how it funds the development and potential commercialization of its drugs. This is a high-risk strategy that requires significant, long-term investment.
Market segment debts - Pharma eyes
KALA BIO is a biotech company specializing in the treatment of eye diseases. Developing ophthalmic drugs is a niche but complex field. This chart shows how the company funds its research and development to bring new treatments to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio KALA BIO Inc.
KALA BIO is a biopharmaceutical company focused on eye diseases. This chart shows how much it relies on debt to fund its research and development. In pharmaceuticals, the path from lab to pharmacy is long and expensive, and debt burden is a measure of the financial risk along the way.
Market segment debt to market segment book capitalization - Pharma eyes
KALA BIO is a biopharmaceutical company focused on developing therapeutics for eye diseases. This chart shows the overall debt burden in the ophthalmic pharmaceutical sector. It helps understand how the industry finances its expensive research and development, and how KALA BIO, following its restructuring, manages its capital.
Debt to book value of all companies in the market
KALA BIO is a biopharmaceutical company focused on eye diseases. After selling its commercial products, it returned to the R&D stage, which is typical for biotech companies. This graph of the company's overall market debt doesn't reflect its specific nature, as the company's survival now depends not on debt management but on laboratory success and investor confidence.
P/E of the company, segment and market as a whole
P/E - KALA BIO Inc.
For KALA BIO, Inc., a biopharmaceutical company focused on treating eye diseases, this chart illustrates investor expectations. Its value is based not on current profits, but on the company's potential for scientific development and its ability to bring new, effective ophthalmological drugs to market.
P/E of the market segment - Pharma eyes
Eye disease treatment, KALA BIO's specialty, is a large market. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that KALA, after its restructuring and divestitures, is valued based on the potential of its remaining developments and its ability to bring them to market.
P/E of the market as a whole
KALA BIO, Inc. is a biopharmaceutical company focused on developing innovative treatments for rare eye diseases. The company uses its platform to deliver drugs to the eye. This biotech sentiment chart helps understand how the market views KALA BIO's scientific potential and its ability to bring new drugs to market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company KALA BIO Inc.
KALA BIO is a biotech company focused on developing therapeutics for rare eye diseases. This chart illustrates investor expectations, which are entirely dependent on the success of its new platform and clinical trials. The trend reflects the market's assessment of the scientific and commercial potential of its developments.
%20P%2FE%20KALA%20BIO%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-KALA-BIO-Inc.&v=1772644743077 "Chart of the company's future (projected) P/E KALA BIO Inc.")
Future (projected) P/E of the market segment - Pharma eyes
KALA BIO is a biotechnology company specializing in the development of drugs for the treatment of eye diseases. This chart shows average profitability expectations for the ophthalmology sector. It provides insight into how investors view the company's scientific platform and the potential of its drug candidates to address unmet medical needs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772644743113 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
KALA BIO, Inc. is a biopharmaceutical company focused on developing treatments for eye diseases. This chart shows investors' risk appetite. For a company operating in the highly specialized field of ophthalmology, it reflects the market's willingness to finance long-term, risky research and development to create new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772644743121 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit KALA BIO Inc.
KALA BIO, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. The financial result illustrated in this chart consists of clinical research expenses. It shows the cost of developing innovative ophthalmic therapies and the path to their potential commercialization.
Profit of companies in the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company focused on the development and commercialization of innovative treatments for eye diseases. Its technology enables efficient drug delivery to ocular tissue. This graph highlights the profit potential in ophthalmology, where unmet medical needs and an aging population create a large and growing market.
Overall market profit
KALA BIO is a biotech company focused on treating rare eye diseases. After a series of setbacks, it restructured its business. Its survival and future success depend on the success of new developments and its ability to attract capital. This chart illustrates the general market environment in which such companies struggle to secure funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company KALA BIO Inc.
KALA BIO is a biopharmaceutical company specializing in the development of drugs for the treatment of rare eye diseases. The profit/loss forecast in this chart reflects analysts' expectations for the success of clinical trials and the commercial potential of its ophthalmology developments.
%20profit%20of%20the%20company%20KALA%20BIO%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-KALA-BIO-Inc.&v=1772644743242 "Graph of future (projected) profit of the company KALA BIO Inc.")
Future (predicted) profit of companies in the market segment - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for eye diseases. This chart shows the revenue forecast for the ophthalmic pharmaceutical sector, allowing one to assess the market perception of the commercial potential of KALA BIO's portfolio in this specialized area of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772644743255 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
KALA BIO is a biopharmaceutical company focused on eye diseases. Its success depends on clinical trial results and regulatory approval. This schedule, reflecting overall market sentiment, impacts the availability of funding needed to conduct expensive research and bring drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772644743304 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - KALA BIO Inc.
KALA BIO is a biopharmaceutical company focused on developing therapies for rare eye diseases. This chart shows how investors assess its potential. This revenue estimate is a bet on the success of its clinical trials and its ability to bring new treatments to market for ophthalmological diseases.
P/S market segment - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company developing treatments for eye diseases based on its proprietary drug delivery technology. This chart shows the industry average market capitalization to revenue ratio. It reflects investor expectations for KALA BIO's clinical programs and the potential of its platform to improve eye disease treatment.
P/S of the market as a whole
KALA BIO (formerly Kala Pharmaceuticals) is a biopharmaceutical company focused on developing treatments for eye diseases using its unique drug delivery technology. This overall market valuation chart helps understand how investors value specialized biotech companies targeting specific therapeutic niches.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company KALA BIO Inc.
KALA BIO is a biopharmaceutical company developing treatments for rare eye diseases. This chart shows its valuation relative to future projected sales. It reflects investor expectations for the success of its new strategy and clinical development in ophthalmology following the sale of its commercial assets.
%20P%2FS%20KALA%20BIO%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-KALA-BIO-Inc.&v=1772644743394 "The graph of the company's future (projected) P/S KALA BIO Inc.")
Future (projected) P/S of the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company that, following the sale of its commercial ophthalmology business, is focusing on developing therapeutics for rare diseases. This chart reflects investor expectations for its new strategy and potential future revenue from its R&D platform, not from past sales.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772644743406 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
KALA BIO is a biopharmaceutical company focused on the treatment of eye diseases. Its future depends on the success of its developments and regulatory approvals. This general expectations chart for KALA is not a direct driver. Demand for effective treatments for ophthalmological diseases is determined by medical needs and is not dependent on the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772644743407 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales KALA BIO Inc.
This chart illustrates the financial trajectory of a biotech company. For KALA BIO, which focuses on treating rare eye diseases, it reflects the funds raised from investors to fund clinical trials after the sale of its commercial portfolio.
Sales of companies in the market segment - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of ophthalmic diseases. Its success depends on the approval and commercialization of its products. This chart shows revenue in the ophthalmic pharmaceutical sector. KALA's innovative drug delivery methods have the potential to improve treatment and contribute to market growth.
Overall market sales
KALA BIO is a biotechnology company focused on developing treatments for eye diseases. Its success depends on the approval and commercialization of new drugs. The company's activities are part of the innovative healthcare sector, which creates new markets and technologies to improve quality of life, contributing to the overall economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company KALA BIO Inc.
KALA BIO is a biopharmaceutical company focused on developing innovative treatments for eye diseases. Its future sales forecast depends on the success of clinical trials and the commercialization of its ophthalmic products.
%20sales%20of%20the%20company%20KALA%20BIO%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-KALA-BIO-Inc.&v=1772644743426 "Schedule of future (projected) sales of the company KALA BIO Inc.")
Future (projected) sales of companies in the market segment - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company focused on treating eye diseases. The forecast for the ophthalmic pharmaceutical sector highlights demand driven by an aging population. The graph reflects the significant need for new treatments for conditions such as dry eye syndrome.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772644743436 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
KALA BIO is a biopharmaceutical company developing therapies for rare eye diseases. The company's success depends on clinical trial results and regulatory approval. This overall economic activity schedule does not impact medical need, but it may impact the investment climate in the biotech sector and the availability of capital for research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772644743438 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality KALA BIO Inc.
KALA BIO is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. While in the commercialization and research stages, it incurs significant expenses. This chart shows its path to profitability, balancing sales revenue with investments in expanding its product portfolio.
Market segment marginality - Pharma eyes
KALA BIO, Inc. is a biopharmaceutical company focused on developing treatments for eye diseases. Being in the clinical stage, its financial metrics reflect intensive investment in R&D. This chart helps understand KALA BIO's operating model compared to other companies operating in the ophthalmology sector.
Market marginality as a whole
KALA BIO, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. This chart shows total revenue. In this context, KALA is an example of a biotech company that, after experiencing setbacks in one area, is seeking new opportunities. Its path to profitability lies in successfully refocusing its research and development efforts.
Employees in the company, segment and market as a whole
Number of employees in the company KALA BIO Inc.
KALA BIO (formerly Kala Pharmaceuticals) is a biopharmaceutical company focused on treating eye diseases. Its workforce dynamics in this chart reflect its business cycle. Growth was driven by the creation of a commercial team to launch drugs, while subsequent layoffs were due to restructuring following asset sales and a refocus on R&D.
Share of the company's employees KALA BIO Inc. within the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company that uses its unique technology to deliver drugs to the anterior and posterior surfaces of the eye. This chart illustrates its scientific specialization. It reflects the percentage of scientists and researchers working in the niche field of ophthalmic pharmacology and the development of new delivery systems that KALA attracts.
Number of employees in the market segment - Pharma eyes
KALA BIO is a biopharmaceutical company focused on treating eye diseases. This chart shows the dynamics in the highly specialized field of ophthalmology. The growing number of scientists and clinicians here signifies progress in the development of new drug delivery methods that could improve the treatment of common conditions like dry eye syndrome.
Number of employees in the market as a whole
KALA BIO, Inc. is a pharmaceutical company specializing in the treatment of eye diseases. Their success is determined not by the economic situation, as reflected in this chart, but by clinical trial results and regulatory approvals. A positive FDA approval can change a company's fortunes overnight, opening access to the market and stimulating the expansion of their commercial team.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company KALA BIO Inc. (KALA)
KALA BIO is a biopharmaceutical company focused on developing therapies for rare eye diseases. This chart demonstrates a science-driven business. Its high market capitalization per employee reflects the market's assessment of the potential of its unique developments to address unmet medical needs, rather than current revenue or headcount.
%20of%20the%20company%20KALA%20BIO%20Inc.%20(KALA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-KALA-BIO-Inc.-KALA&v=1772644743560 "Chart of market capitalization per employee (in thousands of dollars) of the company KALA BIO Inc. (KALA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
KALA BIO specializes in developing drugs for the treatment of eye diseases, a highly specialized area of biopharmaceuticals. This chart shows how the market values the scientific potential of a small but focused team. The high cost per employee reflects investors' high expectations for the approval and commercial success of its drugs.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772644743591 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
KALA BIO (formerly Kala Pharmaceuticals) is a biopharmaceutical company focused on treating eye diseases. This chart demonstrates the company's high employee value, as the development and commercialization of even one successful ophthalmology drug can generate significant revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772644743624 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company KALA BIO Inc. (KALA)
KALA BIO is a biotech company focused on treating rare eye diseases. They use their platform to deliver drugs to hard-to-reach tissues in the eye. They are an R&D company. This metric is likely negative. It reflects how much the company invests in each scientist to develop and test their innovative ophthalmic drugs.
%20Chart%20KALA%20BIO%20Inc.%20(KALA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-KALA-BIO-Inc.-KALA&v=1772644743672 "Company Profit Per Employee (in thousands of dollars) Chart KALA BIO Inc. (KALA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
KALA BIO (KALA) is a biotech company focused on treating eye diseases. As with many biotechs in the R&D stage, this graph serves as a guide to the future. Current profitability is negative due to research costs. KALA's success will depend on the approval of their drugs, which will allow them to monetize the years of work of their scientific team.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772644743675 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
KALA BIO (KALA) is a biotech company focused on eye diseases. After selling its commercial products, the company returned to the R&D stage. This graph likely shows negative profitability, reflecting a shift to a model of pure investment in the scientific team to develop a new therapeutic platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772644743689 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee KALA BIO Inc. (KALA)
KALA BIO is a biotech company focused on ophthalmology. This chart reflects its current status as an R&D organization following the sale of its commercial assets. Zero revenue is normal. This metric demonstrates potential: successful development of a new drug could lead to explosive growth in revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-KALA-BIO-Inc.-KALA&v=1772644743697 "Sales chart per company employee KALA BIO Inc. (KALA)")
Sales per employee in the market segment - Pharma eyes
KALA BIO is a biotech company focused on developing therapeutics for rare eye diseases. At the R&D stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee. This is a key indicator for assessing progress in this niche medical field.
Sales per employee for the market as a whole
KALA BIO is a biotech company focused on treating eye diseases. They have both approved products and an R&D pipeline. This graph shows revenue per employee. It reflects the commercial success of their eye medications and the efficiency of their small team, which must cover both R&D and sales.
Short shares by company, segment and market as a whole
Shares shorted by company KALA BIO Inc. (KALA)
KALA BIO (formerly Kala Pharmaceuticals) is a biotech company that, after selling its commercial ophthalmology business, is now focusing on developing new drugs. This chart indicates bearish bets. Bears may doubt the success of the new strategy and whether the company has sufficient funds to advance its developments through costly clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-KALA-BIO-Inc.-KALA&v=1772644743779 "Short Shares Chart for the Company KALA BIO Inc. (KALA)")
Shares shorted by market segment - Pharma eyes
KALA BIO (formerly KALA Pharmaceuticals) is a biotech company focused on treating eye diseases. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA).
Shares shorted by the overall market
KALA BIO (KALA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing KALA will be unable to raise funds for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator KALA BIO Inc. (KALA)
KALA BIO is a biotech company focused on eye diseases. The stock is speculative and dependent on R&D. This chart can surge above 70 on positive trial data or FDA approvals. Oversold territory (<30) often reflects setbacks, delays, or funding concerns, indicating investor pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-KALA-BIO-Inc.-KALA&v=1772644743876 "RSI 14 indicator chart for the company's stock KALA BIO Inc. (KALA)")
RSI 14 Market Segment - Pharma eyes
KALA BIO (KALA) is a biotech company focused *only* on treating *eye* diseases (ophthalmology). The "Pharma Eyes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is KALA's growth due to its R&D or is *the entire* biotech industry simply overheated?
RSI 14 for the overall market
KALA BIO, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like KALA are forced to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KALA (KALA BIO Inc.)
KALA BIO (formerly Kala Pharmaceuticals) is a biotech company focused on treating rare eye diseases. This chart shows the average 12-month analyst price target. Their target price is a collective speculative bet on the success of clinical trials and approval of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KALA-KALA-BIO-Inc.&v=1772644743985 "A chart showing analyst consensus forecasts for the expected stock price. KALA (KALA BIO Inc.)")
The difference between the consensus estimate and the actual stock price KALA (KALA BIO Inc.)
KALA BIO (KALA) is a biopharmaceutical company that has "rebooted" and is now focusing on developing therapies for rare retinal diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their new pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KALA-KALA-BIO-Inc.&v=1772644743986 "A chart showing the difference between the consensus forecast and the actual stock price. KALA (KALA BIO Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
KALA BIO is a biotech company that sold its commercial eye drops to focus entirely on a risky R&D platform. This chart shows analysts' overall expectations for the entire ophthalmic pharmaceutical sector. It reflects whether experts believe R&D startups can succeed.
Analysts' consensus forecast for the overall market share price
KALA BIO (formerly KALA Pharmaceuticals) is a biotech company that, having divested its commercial eye drugs, is now focusing on developing therapies for rare diseases. This chart shows the overall risk appetite. For KALA, a company in a state of complete transformation, overall market optimism is critical to funding their new, risky venture.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index KALA BIO Inc.
KALA BIO (formerly Kala Pharmaceuticals) is a biotech company that, after selling its commercial eye drugs, completely rebooted itself. They are now focusing on R&D in bioadhesive drug delivery technologies. This chart is a summary indicator of their second chance. It reflects their new, focused R&D pipeline and their ability to survive this radical restructuring.
AKIMA Market Segment Index - Pharma eyes
KALA BIO is a biotech company that, after selling its ophthalmology assets, is now focusing on developing therapies for rare genetic diseases. This chart shows the average pharmaceutical sector index, allowing investors to assess how KALA's new strategic pivot compares to the average pharmaceutical company.
The AKIM Index for the overall market
KALA BIO is a biotech company developing treatments for rare and severe eye diseases (corneal epithelial defects). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific enterprise, which seeks to address unmet medical needs, compares to overall economic trends.
